Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) and Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of current ratings for Cumberland Pharmaceuticals and Ocular Therapeutix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cumberland Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Ocular Therapeutix | 1 | 1 | 9 | 0 | 2.73 |
Ocular Therapeutix has a consensus price target of $24.33, suggesting a potential upside of 249.62%. Given Ocular Therapeutix’s stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Cumberland Pharmaceuticals.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cumberland Pharmaceuticals | $44.52 million | 2.49 | -$2.84 million | ($0.71) | -10.41 |
| Ocular Therapeutix | $51.95 million | 29.42 | -$265.94 million | ($1.42) | -4.90 |
Cumberland Pharmaceuticals has higher earnings, but lower revenue than Ocular Therapeutix. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cumberland Pharmaceuticals and Ocular Therapeutix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cumberland Pharmaceuticals | -34.40% | -28.81% | -9.25% |
| Ocular Therapeutix | -579.10% | -59.89% | -45.99% |
Volatility & Risk
Cumberland Pharmaceuticals has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Insider & Institutional Ownership
15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Ocular Therapeutix beats Cumberland Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
